Ventura Elisa, Sassi Francesca, Fossati Sara, Parodi Arianna, Blalock William, Balza Enrica, Castellani Patrizia, Borsi Laura, Carnemolla Barbara, Zardi Luciano
Laboratory of Recombinant Therapeutic Proteins, Advanced Biotechnology Centre, Istituto G Gaslini, Genoa, Italy.
J Biol Chem. 2009 Sep 25;284(39):26646-54. doi: 10.1074/jbc.M109.025924. Epub 2009 Jul 24.
We report a novel strategy to engineer and express stable and soluble human recombinant polyvalent/polyspecific fusion proteins. The procedure is based on the use of a central skeleton of uteroglobin, a small and very soluble covalently linked homodimeric protein that is very resistant to proteolytic enzymes and to pH variations. Using a human recombinant antibody (scFv) specific for the angiogenesis marker domain B of fibronectin, interleukin 2, and an scFv able to neutralize tumor necrosis factor-alpha, we expressed various biologically active uteroglobin fusion proteins. The results demonstrate the possibility to generate monospecific divalent and tetravalent antibodies, immunocytokines, and dual specificity tetravalent antibodies. Furthermore, compared with similar fusion proteins in which uteroglobin was not used, the use of uteroglobin improved properties of solubility and stability. Indeed, in the reported cases it was possible to vacuum dry and reconstitute the proteins without any aggregation or loss in protein and biological activity.
我们报告了一种构建并表达稳定且可溶的人重组多价/多特异性融合蛋白的新策略。该方法基于使用子宫珠蛋白的中央骨架,子宫珠蛋白是一种小的、高度可溶的共价连接的同二聚体蛋白,对蛋白水解酶和pH变化具有很强的抗性。利用针对纤连蛋白血管生成标记结构域B的人重组抗体(单链抗体片段)、白细胞介素2以及一种能够中和肿瘤坏死因子-α的单链抗体片段,我们表达了多种具有生物活性的子宫珠蛋白融合蛋白。结果证明了生成单特异性二价和四价抗体、免疫细胞因子以及双特异性四价抗体的可能性。此外,与未使用子宫珠蛋白的类似融合蛋白相比,子宫珠蛋白的使用改善了溶解性和稳定性。实际上,在所报道的案例中,可以对蛋白质进行真空干燥和复溶,而不会发生任何聚集,蛋白质和生物活性也不会丧失。